U.S. markets closed

Theralink Technologies, Inc. (OBMP)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1196+0.0196 (+19.60%)
At close: 9:30AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1196 - 0.1196
52 Week Range0.1000 - 10.0000
Avg. Volume3,824
Market Cap664.434M
Beta (5Y Monthly)2.77
PE Ratio (TTM)N/A
EPS (TTM)-16.9520
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    The Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID stocks) soared in 2019. They have underperformed large-caps over the past 12 months, but still may be in a better position to generate market-beating returns going forward. For one thing, SMID companies tend to focus on domestic markets, so their businesses could be poised to rebound more quickly once COVID-19 vaccines are more widely distributed and the domestic service economy recovers. As well, the prices of SMID stocks generally are lower than the prices of large-caps. That said, SMID stocks can be risky. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record. Investors used to use a $2 billion market-cap threshold to define a small-cap stock and a $10 billion threshold for a mid-cap. The Russell 2000 index now includes numerous companies with market capitalizations above $15 billion. For our purposes, we use a threshold of $20 billion to define a SMID stock.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • PR Newswire

    Theralink® Technologies Achieves Major Milestone: California Clinical and Public Health License for its Golden, CO Laboratory

    Theralink Technologies, Inc. (OTC: OBMP), a precision medicine and molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced that the Company has received Clinical and Public Health License from the State of California for its Golden, Colorado laboratory, effective March 11th, 2021.

  • PR Newswire

    Theralink® Technologies Moves Closer Toward Changing the Standard of Care for All Women Newly Diagnosed with HER2+ Breast Cancer

    In a recent announcement by Rutgers Cancer Institute of New Jersey and the Center for Applied Proteomics and Molecular Medicine at George Mason University (CAPMM), Theralink Technologies (OTC: OBMP) ("Theralink" or the "Company"), was named commercial provider of its patented Reverse Phase Protein Array (RPPA) technology for breast cancer patients, if the proposed study has a positive outcome.

  • PR Newswire

    Theralink® Technologies Announces Milestone Event--The Commencement of Testing on its First Patients

    Theralink® Technologies (OTC: OBMP) ("Theralink" or the "Company"), a precision medicine molecular profiling company with a novel phosphoprotein-based Laboratory Developed Test (LDT), today announced that it has begun the testing of its first patients with the Theralink's Reverse Phase Protein Array (RPPA) technology. Theralink's RPPA testing measures the direct activation state for dozens of drug targets at once potentially providing oncologists with key information about the patient's specific tumor. Theralink's unique assay is the only commercial LDT assay on the market that can measure the activation/phosphorylation state of dozens of drug targets directly from a tumor biopsy.